These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30216039)

  • 21. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment.
    Maisonneuve IM; Glick SD
    Pharmacol Biochem Behav; 2003 Jun; 75(3):607-18. PubMed ID: 12895678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Ibogaine--the substance for treatment of toxicomania. Neurochemical and pharmacological action].
    Kazlauskas S; Kontrimaviciūte V; Sveikata A
    Medicina (Kaunas); 2004; 40(3):216-9. PubMed ID: 15064541
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.
    Vastag B
    Science; 2005 Apr; 308(5720):345-6. PubMed ID: 15831735
    [No Abstract]   [Full Text] [Related]  

  • 24. A non-hallucinogenic psychedelic analogue with therapeutic potential.
    Cameron LP; Tombari RJ; Lu J; Pell AJ; Hurley ZQ; Ehinger Y; Vargas MV; McCarroll MN; Taylor JC; Myers-Turnbull D; Liu T; Yaghoobi B; Laskowski LJ; Anderson EI; Zhang G; Viswanathan J; Brown BM; Tjia M; Dunlap LE; Rabow ZT; Fiehn O; Wulff H; McCorvy JD; Lein PJ; Kokel D; Ron D; Peters J; Zuo Y; Olson DE
    Nature; 2021 Jan; 589(7842):474-479. PubMed ID: 33299186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.
    Mash DC
    Pharmacol Res; 2023 Apr; 190():106620. PubMed ID: 36907284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats.
    Rodrı Guez P; Urbanavicius J; Prieto JP; Fabius S; Reyes AL; Havel V; Sames D; Scorza C; Carrera I
    ACS Chem Neurosci; 2020 Jun; 11(11):1661-1672. PubMed ID: 32330007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic plasticity and the energy economizing effect of ibogaine, the principal alkaloid of Tabernanthe iboga.
    Paškulin R; Jamnik P; Danevčič T; Koželj G; Krašovec R; Krstić-Milošević D; Blagojević D; Strukelj B
    J Ethnopharmacol; 2012 Aug; 143(1):319-24. PubMed ID: 22751004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus.
    Helsley S; Filipink RA; Bowen WD; Rabin RA; Winter JC
    Pharmacol Biochem Behav; 1998 Feb; 59(2):495-503. PubMed ID: 9477000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iboga interactions with psychomotor stimulants: panacea in the paradox?
    Szumlinski KK; Maisonneuve IM; Glick SD
    Toxicon; 2001 Jan; 39(1):75-86. PubMed ID: 10936624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelic Therapy: A Primer for Primary Care Clinicians-Ibogaine.
    Cherian K; Shinozuka K; Tabaac BJ; Arenas A; Beutler BD; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e133-e140. PubMed ID: 38518270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration.
    Glick SD; Maisonneuve IM; Kitchen BA; Fleck MW
    Eur J Pharmacol; 2002 Mar; 438(1-2):99-105. PubMed ID: 11906717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences.
    Rodríguez-Cano BJ; Kohek M; Ona G; Alcázar-Córcoles MÁ; Dos Santos RG; Hallak JEC; Bouso JC
    Drug Alcohol Rev; 2023 Feb; 42(2):401-414. PubMed ID: 36456173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neurotrophic mechanisms of psychedelic therapy].
    Corne R; Mongeau R
    Biol Aujourdhui; 2019; 213(3-4):121-129. PubMed ID: 31829932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of ibogaine and noribogaine in biological fluids and hair by LC-MS/MS after Tabernanthe iboga abuse Iboga alkaloids distribution in a drowning death case.
    Chèze M; Lenoan A; Deveaux M; Pépin G
    Forensic Sci Int; 2008 Mar; 176(1):58-66. PubMed ID: 18024037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.
    Heink A; Katsikas S; Lange-Altman T
    J Psychoactive Drugs; 2017; 49(3):201-208. PubMed ID: 28266890
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibogaine signals addiction genes and methamphetamine alteration of long-term potentiation.
    Onaivi ES; Ali SF; Chirwa SS; Zwiller J; Thiriet N; Akinshola BE; Ishiguro H
    Ann N Y Acad Sci; 2002 Jun; 965():28-46. PubMed ID: 12105083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias.
    Grogan J; Gerona R; Snow JW; Kao L
    J Emerg Med; 2019 Oct; 57(4):e99-e104. PubMed ID: 31630892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.
    Dunlap LE; Andrews AM; Olson DE
    ACS Chem Neurosci; 2018 Oct; 9(10):2408-2427. PubMed ID: 30001118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-HIV-1 activity of the Iboga alkaloid congener 18-methoxycoronaridine.
    Silva EM; Cirne-Santos CC; Frugulhetti IC; Galvão-Castro B; Saraiva EM; Kuehne ME; Bou-Habib DC
    Planta Med; 2004 Sep; 70(9):808-12. PubMed ID: 15386189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Data accrue on "visionary" agent to interrupt addiction.
    Morris K
    Lancet; 1999 Nov; 354(9193):1883. PubMed ID: 10584734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.